EarningsTarsus reported Xdemvy revenue of $102.7 million in the second quarter, significantly beating both the estimate of $98.4 million and consensus of $96.3 million.
Market PenetrationPrescriber base has expanded beyond the initial target with now more than 20,000 prescribing Xdemvy, providing a strong foundation of script volume moving forward.
Product DemandXDEMVY generated $78.3M in net product sales, reflecting 217% year-over-year growth and quarterly 18% growth from the previous quarter.